Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.65 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.54 |
| ▸ | WIZ | O95785 | 1/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046071 | 1.00 | CRBN (0.65) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| SCHEMBL29547243 | 1.00 | CRBN (0.65) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| SCHEMBL20211856 | 1.00 | CRBN (0.65) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| Hydrochloric Acid SCHEMBL22581027 | 0.99 | CRBN (0.64) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| Hydrochloric Acid SCHEMBL20211892 | 0.99 | CRBN (0.64) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| Hydrochloric Acid SCHEMBL30720151 | 0.99 | CRBN (0.64) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| Hydrochloric Acid SCHEMBL30433803 | 0.99 | CRBN (0.64) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| SCHEMBL20231641 | 0.97 | CRBN (0.61) | CRBNIKZF2WIZCSNK1A1 | |
| SCHEMBL31131377 | 0.97 | CRBN (0.61) | CRBNIKZF2WIZCSNK1A1 | |
| Hydrochloric Acid SCHEMBL30906265 | 0.96 | CRBN (0.60) | CRBNIKZF2WIZCSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| US-20250320195-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250177539-A1 | ER DEGRADERS AND USES THEREOF | ASTRAZENECA AB (SE) | 2025-06-05 | — | — | US | disclosed |
| EP-4543871-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-12172981-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| CN-118834201-A | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degrading agents | 阿尔维纳斯运营股份有限公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-110291087-B | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degrading agents | 阿尔维纳斯运营股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240190842-A1 | SUBSTITUTED QUINOLINONE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-06-13 | — | — | US | disclosed |
| WO-2024102784-A1 | SUBSTITUTED QUINOLINONE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-3689868-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3689868-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| CN-111454248-A | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | 阿尔维纳斯运营股份有限公司 | 2020-07-28 | — | — | CN | disclosed |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3548483-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-06-07 | — | — | US | disclosed |
| WO-2018102725-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018102725-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190842-A1 | SUBSTITUTED QUINOLINONE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN DEGRADATION ACTIVITY AND USES THEREOF | AR, NR5A1, CYP19A1 | CRBN 191/4885IKZF2 4231/4885WIZ 4725/4885 |
| US-12172981-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | MDM2, CRBN, VHL | CRBN 2/4885IKZF2 1564/4885WIZ 2630/4885 |
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | CRBN 488/4885IKZF2 2456/4885WIZ 4179/4885 |
| US-20250320195-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | CRBN 2/4885IKZF2 1564/4885WIZ 2630/4885 |
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | CRBN 298/4885IKZF2 2350/4885WIZ 1620/4885 |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | CRBN 2/4885IKZF2 1564/4885WIZ 2630/4885 |
| US-20250177539-A1 | ER DEGRADERS AND USES THEREOF | ESR1, ESR2, ESRRA | CRBN 1588/4885IKZF2 1412/4885WIZ 3784/4885 |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | MDM2, CRBN, VHL | CRBN 2/4885IKZF2 1564/4885WIZ 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.